{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059152","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.749327+00:00","generated_at":"2026-06-02T00:45:31.323162+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M","bullets":["Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.","Gross margin 46.3%, best in 12 quarters, up from 43.0% in Q1 2023.","Operating loss $0.6M vs operating income $5.8M in Q1 2023 (due to reversal of accrued payroll tax of $6.2M).","Adjusted EBITDA negative $0.5M vs negative $0.2M in Q1 2023; cash $0.7M down from $1.3M.","Acquired Elevated Softgels, a Colorado softgel and tincture manufacturer; no deal terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059152","json":"https://secwatch.observer/filing/0000950170-24-059152.json","markdown":"https://secwatch.observer/filing/0000950170-24-059152.md","text":"https://secwatch.observer/filing/0000950170-24-059152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/0000950170-24-059152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/cvsi-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:45:31.323162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df413f52cae55d62793a5cc79c34a8d976fc6379","claim":"CV Sciences, Inc. reported for the quarter ended March 31, 2024 results: revenue $4.0 million.","evidence_excerpt":"and products, today announced its financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for first quarter 2024 compared to $4.1 million for the first quarter 2023 and a sequential improvement from $3.8 million for the fourth quarter 2023; • Recognized gross margin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024059152/0000950170-24-059152-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2024"},{"label":"Revenue","value":"$4.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}